European equities traded in the US as American depositary receipts were tracking higher late Thursday morning, rising 0.57% to 1,421.23 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Biotech (EVAX), which rose 4.3% and 3.1% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and telecommunications company Ericsson (ERIC), which were up 2.8% and 1.7% respectively.
The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and internet advertising firm Criteo (CRTO), which dropped 21% and 3.1% respectively. They were followed by accommodations booking company trivago (TRVG) and biopharmaceutical company DBV Technologies (DBVT), which lost 3% and 2.2% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company NuCana (NCNA) and utilities company National Grid (NGG), which advanced 39% and 3.3% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and medical device maker Smith & Nephew (SNN), which increased 2.5% and 2.1% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Mereo BioPharma Group (MREO), which fell 6.9% and 5.8% respectively. They were followed by biopharmaceutical company Adaptimmune (ADAP) and software firm Endava (DAVA), which were down 4.8% and 4.5% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。